HRP20180234T1 - Postupci presavijanja g-csf iz inkluzijskih tijela - Google Patents
Postupci presavijanja g-csf iz inkluzijskih tijela Download PDFInfo
- Publication number
- HRP20180234T1 HRP20180234T1 HRP20180234TT HRP20180234T HRP20180234T1 HR P20180234 T1 HRP20180234 T1 HR P20180234T1 HR P20180234T T HRP20180234T T HR P20180234TT HR P20180234 T HRP20180234 T HR P20180234T HR P20180234 T1 HRP20180234 T1 HR P20180234T1
- Authority
- HR
- Croatia
- Prior art keywords
- csf
- solubilizing agent
- carried out
- exchange chromatography
- resin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 21
- 210000003000 inclusion body Anatomy 0.000 title claims 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 18
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 18
- 239000002904 solvent Substances 0.000 claims 14
- 239000011347 resin Substances 0.000 claims 10
- 229920005989 resin Polymers 0.000 claims 10
- 238000005571 anion exchange chromatography Methods 0.000 claims 6
- 238000004255 ion exchange chromatography Methods 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- 238000005277 cation exchange chromatography Methods 0.000 claims 5
- 238000010828 elution Methods 0.000 claims 5
- 230000003647 oxidation Effects 0.000 claims 4
- 238000007254 oxidation reaction Methods 0.000 claims 4
- 239000003957 anion exchange resin Substances 0.000 claims 3
- 239000012149 elution buffer Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical group CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000003729 cation exchange resin Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 238000005498 polishing Methods 0.000 claims 2
- 108700004121 sarkosyl Proteins 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003916 acid precipitation Methods 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229940023913 cation exchange resins Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Claims (19)
1. Postupak presavijanja čimbenika stimuliranja kolonija granulocita (G-CSF) iz inkluzijskih tijela, naznačen time što se sastoji u:
a) solubiliziranju G-CSF u prisutnosti sredstva za solubiliziranje;
b) provođenju oksidiranja i koraka prvog presavijanja, koji se sastoji u inkubiranju solubiliziranog G-CSF u prisutnosti oksidacijskog sredstva i sredstva za solubiliziranje;
c) uklanjanju sredstva za solubiliziranje adsorpcijom na ionskoizmjenjivačku smolu i/ili ionskoizmjenjivačkom kromatografiju, uz moguće provođenje kiselog taloženja; i
d) provođenju koraka drugog presavijanja, koji se sastoji u razrjeđivanju niskovodljivim puferom, ili poželjnije vodom, uz inkubiranje G-CSF u koraku (c),
gdje se korak drugog presavijanja provodi u niskovodljivom puferu, s vodljivošću od u najmanju ruku ispod 2 mS/cm i u trajanju od više od 12 sati.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što su inkluzijska tijela od mikroorganizma, po mogućnosti od bakterije E. coli.
3. Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je G-CSF rekombinantni goveđi ili ljudski metionil-G-CSF.
4. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je sredstvo za solubiliziranje N-lauroilsarkozin.
5. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je oksidacijsko sredstvo CuSO4.
6. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se solubiliziranje G-CSF provodi kod vrijednosti pH iznad pH 7.
7. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je sredstvo za solubiliziranje N-lauroilsarkozin, u koncentraciji od 0,5% to 1,5%.
8. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se oksidiranje i korak prvog presavijanja provodi u trajajnu od najmanje dva sata.
9. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se oksidiranje i korak prvog presavijanja provodi pod strujom zraka i bez hlađenja.
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se oksidiranje i korak prvog presavijanja provodi kod vrijednosti pH od 7-9 i/ili na temperaturi od 20-28 °C i/ili u trajanju od 15-25 sati.
11. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uklanjanje sredstva za solubiliziranje u koraku (c) se sastoji u: AEX i CEX, moguće tim redoslijedom.
12. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uklanjanje sredstva za solubiliziranje u koraku (c) se sastoji u:
a) vezanju na anionskoizmjenjivački smolni materijal miješanjem otopine G-CSF sa suspendiranim smolnim materijalom i uklanjanje smolnog materijala filtriranjem, i/ili
b) ionskoizmjenjivačkoj kromatografiji u uvjetima gdje se sredstvo za solubiliziranje veže na smolu, a G-CSF zaostaje u protoku i/ili,
c) ionskoizmjenjivačkoj kromatografiji u uvjetima gdje se G-CSF veže na smolu, a sredstvo za solubiliziranje zaostaje u protoku.
13. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sredstvo za solubiliziranje i druge nečistoće uklanja uzastopnom primjenom sljedećih koraka:
(i) AEX,
(ii) kiselog taloženja,
(iii) AEX, i
(iv) CEX.
14. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sredstvo za solubiliziranje i druge nečistoće uklanja uzastopnom primjenom sljedećih koraka:
a) vezanja sredstva za solubiliziranje na anionskoizmjenjivački smolni materijal miješanjem otopine G-CSF sa suspendiranim smolnim materijalom i uklanjanja smolnog materijala filtriranjem;
b) taloženja nečistoća snižavanjem pH ispod pH 5 i uklanjanjem taloga filtriranjem;
c) anionskoizmjenjivačku kromatografiju, koju se provodi u uvjetima u kojima se preostalo sredstvo za solubiliziranje veže na smolu, a G-CSF zaostaje u protoku;
d) kationskoizmjenjivačku kromatografiju, koju se provodi u uvjetima u kojima se G-CSF veže na smolu, a preostalo sredstvo za solubiliziranje zaostaje u protoku; i
e) eluiranja vezanog G-CSF s kationskoizmjenjivačke smole stupnjevitim ili gradijentnim eluiranjem upotrebom pufera za eluiranje uz povećani pH ili koncentraciju soli.
15. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak drugog presavijanja provodi u uvjetima hlađenja.
16. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak drugog presavijanja provodi na temperaturi od 2-8 °C i/ili u trajajnu od najmanje 24 sata.
17. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak drugog presavijanja provodi kod vrijednosti pH iznad pH 7.
18. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što postupak dodatno uključuje korak poliranja, koji se sastoji u jednoj ili više ionskoizmjenjivačkih kromatografija, gdje jedna ili više ionskoizmjenjivačkih kromatografija u koraku poliranja može uključivati anionskoizmjenjivačku kromatografiju, za kojom slijedi kationskoizmjenjivačka kromatografija.
19. Postupak u skladu s patentnim zahtjevom 18, gdje se jedna ili više ionskoizmjenjivačkih kromatografija sastoje u sljedećim koracima:
a) anionskoizmjenjivačke kromatografije, koju se provodi u uvjetima gdje se G-CSF veže na smolu;
b) eluiranja vezanog G-CSF stupnjevitim ili gradijentnim eluiranjem upotrebom pufera za eluiranje uz smanjenu pH ili povećanu koncentraciju soli;
c) kationskoizmjenjivačku kromatografiju, koju se provodi u uvjetima gdje se G-CSF veže na smolu;
d) eluiranja vezanog G-CSF stupnjevitim ili gradijentnim eluiranjem upotrebom pufera za eluiranje uz povećani pH ili koncentraciju soli;
naznačen time što okosnični polimeri smola za anionsku i kationsku izmjenu oba sadrže metakrilatne derivate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1200172A HUP1200172A2 (en) | 2012-03-19 | 2012-03-19 | Methods for refolding g-csf from inclusion bodies |
| PCT/EP2013/055531 WO2013068603A2 (en) | 2012-03-19 | 2013-03-18 | Methods for refolding g-csf from inclusion bodies |
| EP13709470.2A EP2828287B1 (en) | 2012-03-19 | 2013-03-18 | Methods for refolding g-csf from inclusion bodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180234T1 true HRP20180234T1 (hr) | 2018-03-23 |
Family
ID=89990649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180234TT HRP20180234T1 (hr) | 2012-03-19 | 2018-02-07 | Postupci presavijanja g-csf iz inkluzijskih tijela |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9458207B2 (hr) |
| EP (1) | EP2828287B1 (hr) |
| JP (1) | JP6282630B2 (hr) |
| KR (1) | KR101933753B1 (hr) |
| CN (1) | CN104540846B (hr) |
| CA (1) | CA2867796C (hr) |
| DK (1) | DK2828287T3 (hr) |
| ES (1) | ES2664231T3 (hr) |
| HR (1) | HRP20180234T1 (hr) |
| HU (2) | HUP1200172A2 (hr) |
| LT (1) | LT2828287T (hr) |
| NO (1) | NO2828287T3 (hr) |
| PL (1) | PL2828287T3 (hr) |
| SI (1) | SI2828287T1 (hr) |
| WO (1) | WO2013068603A2 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404453B (zh) | 2010-07-30 | 2021-01-05 | Emd密理博公司 | 层析介质和方法 |
| HUP1200171A1 (hu) | 2012-03-19 | 2013-09-30 | Richter Gedeon Nyrt | Módszerek polipeptidek elõállítására |
| EP3084776B1 (de) * | 2013-12-19 | 2018-06-20 | Fraunhofer Gesellschaft zur Förderung der Angewand | Transparente nanodrahtelektrode mit funktionaler organischer schicht |
| CA2954425C (en) | 2014-09-02 | 2019-05-07 | Emd Millipore Corporation | High surface area fiber media with nano-fibrillated surface features |
| KR102162753B1 (ko) | 2014-12-08 | 2020-10-07 | 이엠디 밀리포어 코포레이션 | 혼합층 이온 교환 흡착제 |
| WO2017181920A1 (zh) * | 2016-04-18 | 2017-10-26 | 江苏恒瑞医药股份有限公司 | 一种重组人粒细胞集落刺激因子的制备方法 |
| CN113866327A (zh) * | 2016-12-12 | 2021-12-31 | 邢玉伟 | Lhj增溶剂在难溶食品添加剂定量测定中的应用 |
| CN112566930A (zh) * | 2018-06-19 | 2021-03-26 | 百时美施贵宝公司 | 使用色谱纯化蛋白质的方法 |
| AU2020261942A1 (en) * | 2019-04-24 | 2021-11-04 | Tanvex Biopharma Usa, Inc. | Process for preparing granulocyte-colony stimulating factor |
| US20220251137A1 (en) * | 2019-07-09 | 2022-08-11 | Jennifer Renee HOPP | Temperature-controlled purification of granulocyte-colony stimulating factor |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| DE3537708A1 (de) | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
| US5681720A (en) | 1986-12-23 | 1997-10-28 | Kyowa Hakko Co., Ltd. | DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide |
| JP2796388B2 (ja) * | 1988-05-13 | 1998-09-10 | アムジエン・インコーポレーテツド | Ｇ−ｃｓｆの精製方法 |
| US5055555A (en) | 1989-01-05 | 1991-10-08 | Helmut Sassenfeld | Purification of G-CSF |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| KR100241257B1 (ko) * | 1997-05-22 | 2000-02-01 | 한승수 | 인체 과립구 콜로니 자극 인자 활성물질 및 그것의 제조방법 |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| ATE349460T1 (de) | 1998-07-09 | 2007-01-15 | Barofold Inc | Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck |
| FR2796071B1 (fr) | 1999-07-08 | 2001-09-07 | Hoechst Marion Roussel Inc | Procede de purification de facteur de stimulation de colonies de granulocytes |
| US6606183B2 (en) * | 1999-12-24 | 2003-08-12 | Nippon Oil Corporation | Method for producing a cell for an electrochromic mirror and an electrochromic mirror |
| EP1284987B1 (en) * | 2000-05-16 | 2007-07-18 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
| US20020150979A1 (en) * | 2000-10-04 | 2002-10-17 | Naokazu Naitou | Process for producing a protein |
| SI21102A (sl) | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
| WO2004001056A1 (en) * | 2002-06-24 | 2003-12-31 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
| SI21273A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| DE102004041639A1 (de) | 2004-08-27 | 2006-03-02 | Bioceuticals Arzneimittel Ag | Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies |
| WO2006097944A2 (en) | 2005-03-17 | 2006-09-21 | Zenotech Laboratories Limited | Process for the purification of recombinant granulocyte-colony stimulating factor |
| KR100694994B1 (ko) | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
| DE102005033250A1 (de) * | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
| GB0605684D0 (en) | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
| EP2102355B1 (en) * | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
| JP2012530131A (ja) | 2009-06-16 | 2012-11-29 | ルピン・リミテッド | 組み換えヒト顆粒球コロニー刺激因子の精製のための方法 |
| SI2341061T1 (sl) * | 2009-12-31 | 2013-12-31 | Arven Ilac Sanayi Ve Ticaret A.S. | Nov postopek za pripravo G-CSF-ja (granulocitne kolonije stimulirajočega faktorja) |
| PL2547699T3 (pl) * | 2010-03-17 | 2017-04-28 | Ratiopharm Gmbh | Sposób otrzymywania biologicznie czynnego rekombinowanego ludzkiego g-csf |
| HUP1200171A1 (hu) | 2012-03-19 | 2013-09-30 | Richter Gedeon Nyrt | Módszerek polipeptidek elõállítására |
-
2012
- 2012-03-19 HU HU1200172A patent/HUP1200172A2/hu unknown
-
2013
- 2013-03-18 JP JP2015500867A patent/JP6282630B2/ja not_active Expired - Fee Related
- 2013-03-18 NO NO13709470A patent/NO2828287T3/no unknown
- 2013-03-18 DK DK13709470.2T patent/DK2828287T3/en active
- 2013-03-18 LT LTEP13709470.2T patent/LT2828287T/lt unknown
- 2013-03-18 KR KR1020147029032A patent/KR101933753B1/ko active IP Right Grant
- 2013-03-18 CA CA2867796A patent/CA2867796C/en active Active
- 2013-03-18 US US14/386,128 patent/US9458207B2/en not_active Expired - Fee Related
- 2013-03-18 SI SI201330941T patent/SI2828287T1/en unknown
- 2013-03-18 ES ES13709470.2T patent/ES2664231T3/es active Active
- 2013-03-18 HU HUE13709470A patent/HUE036635T2/hu unknown
- 2013-03-18 CN CN201380015531.1A patent/CN104540846B/zh not_active Expired - Fee Related
- 2013-03-18 WO PCT/EP2013/055531 patent/WO2013068603A2/en active Application Filing
- 2013-03-18 EP EP13709470.2A patent/EP2828287B1/en active Active
- 2013-03-18 PL PL13709470T patent/PL2828287T3/pl unknown
-
2018
- 2018-02-07 HR HRP20180234TT patent/HRP20180234T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2828287A2 (en) | 2015-01-28 |
| US9458207B2 (en) | 2016-10-04 |
| KR20140142724A (ko) | 2014-12-12 |
| JP2015512377A (ja) | 2015-04-27 |
| US20150057439A1 (en) | 2015-02-26 |
| CN104540846B (zh) | 2017-05-24 |
| JP6282630B2 (ja) | 2018-02-21 |
| HUP1200172A2 (en) | 2013-10-28 |
| NO2828287T3 (hr) | 2018-06-16 |
| CA2867796A1 (en) | 2013-05-16 |
| DK2828287T3 (en) | 2018-02-26 |
| WO2013068603A2 (en) | 2013-05-16 |
| WO2013068603A3 (en) | 2013-08-29 |
| KR101933753B1 (ko) | 2018-12-28 |
| CN104540846A (zh) | 2015-04-22 |
| HUE036635T2 (hu) | 2018-07-30 |
| EP2828287B1 (en) | 2018-01-17 |
| PL2828287T3 (pl) | 2018-05-30 |
| SI2828287T1 (en) | 2018-04-30 |
| LT2828287T (lt) | 2018-03-12 |
| CA2867796C (en) | 2019-10-08 |
| ES2664231T3 (es) | 2018-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180234T1 (hr) | Postupci presavijanja g-csf iz inkluzijskih tijela | |
| JP6580650B2 (ja) | フロースルー式での生物製剤からのタンパク質凝集体の除去 | |
| JP6092892B2 (ja) | 抗体の精製方法 | |
| CN104628846B (zh) | 重组蛋白质的纯化方法 | |
| JP5980782B2 (ja) | タンパク質のタンデム精製 | |
| US10053489B2 (en) | Method for purifying antibody | |
| JP2015042645A5 (hr) | ||
| JP3676817B2 (ja) | 新規因子ｉｘ精製法 | |
| JP2012018171A5 (hr) | ||
| JP2017086090A5 (hr) | ||
| HRP20180182T1 (hr) | Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa | |
| RU2015120458A (ru) | Очистка полипептидов с использованием двухстадийной ультрафильтрации в тангенциальном потоке | |
| JP2015512377A5 (hr) | ||
| MX2012009283A (es) | Purificacion de anticuerpo de una unidad. | |
| HRP20192217T1 (hr) | ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE | |
| JP2014507368A5 (hr) | ||
| RU2013124062A (ru) | Способы захвата представляющих интерес частиц из смеси | |
| JP2017121255A5 (hr) | ||
| CN103497248B (zh) | 一种从细胞培养上清中分离纯化抗体的方法 | |
| Dong et al. | Isolation of immunoglobulin G from bovine milk whey by poly (hydroxyethyl methacrylate)‐based anion‐exchange cryogel | |
| Peram et al. | Monoclonal antibody purification using cationic polyelectrolytes: an alternative to column chromatography | |
| RU2014108241A (ru) | Способ катион- и анионобменной хроматографии | |
| JP2016535071A5 (hr) | ||
| KR20170035980A (ko) | 항체의 정제 방법 | |
| Pavan et al. | The effect of NaCl on the adsorption of human IgG onto CM-Asp–PEVA hollow fiber membrane-immobilized nickel and cobalt metal ions |